MDRX earnings

Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest

Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi

Veradigm Inc. (NASDAQ:MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million. The company also introduced initial financial guidance for Fiscal 2023 as follows: Revenue is expected between $640 million and $660

Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2022. Third quarter 2022 Veradigm revenue was $145 million compared with $137 million in the third quarter of 2021. On a consolidated Allscripts basis third quarter 2022 revenue was $152 million compared with $145 million in the third quarter of 2021. On a GAAP basis, Veradigm income from operations was $28 million in the third quarter of 202

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended September 30, 2022 after the close of stock market hours on Thursday, November 3, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Third-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, November 3, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts I

Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021 Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2022. Second quarter 2022 Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021. On a consolidated Allscripts basis second quarter 2022 revenue was $151 million compared with $141 million in the second quarter of 2021. In the second quarter, Allscripts completed the sale of its Hospital and Large Physician Practices Segment. The

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended June 30, 2022 after the close of stock market hours on Thursday, August 4, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Second-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, August 4, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor

First quarter GAAP diluted EPS of $0.17; non-GAAP diluted EPS of $0.13 Closed the sale of Hospital & Large Physician Practices business segment to Constellation Software Generated $35 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three months ended March 31, 2022. First quarter 2022 Veradigm revenue was $136 million compared with $126 million in the first quarter of 2021. On a consolidated Allscripts basis first quarter 2022 revenue was $143 million compared with $134 million in the first quarter of 2021. On a GAAP basis in the first quarter of 2022, Veradigm in

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended March 31, 2022 after the close of stock market hours on Thursday, May 5, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. First-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, May 5, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor Relati

Allscripts Healthcare Solutions (NASDAQ:MDRX) ("Allscripts") announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation ("Harris"), to sell Harris the net assets of Allscripts Hospitals and Large Physician Practices business segment. The Hospitals and Large Physician Practices business segment includes the Sunrise™, Paragon®, Allscripts TouchWorks®, Allscripts® Opal, STAR™, HealthQuest™ and dbMotion™ solutions. The assets of Allscripts Veradigm business segment are not included in this transaction and will continue to be owned by Allscripts going forward. "The medical industry we faithfully

Fourth quarter GAAP diluted EPS of $0.68; non-GAAP diluted EPS of $0.79 Fourth quarter bookings of $219 million up 21% from the fourth quarter of 2020 Generated $66 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and twelve months ended December 31, 2021. Bookings(1) were $219 million in the fourth quarter of 2021. This result compares with $181 million in the fourth quarter of 2020. Contract revenue backlog totaled $3.8 billion as of December 31, 2021. Fourth quarter 2021 revenue was $392 million compared with $386 million in the fourth quarter of 2020. On

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) today announced preliminary financial results for the three and twelve months ended December 31, 2021. Revenue for the fourth quarter of 2021 is expected to be between $390 million and $395 million. For the full year 2021, the company expects GAAP operating income to be between $70 million and $75 million and expects Adjusted EBITDA(1) to be between $295 million and $300 million, an increase from the prior outlook range of between $275 million and $285 million. The Company also expects full year 2021 cash flow from continuing operations to be between $245 million and $250 million and expects free cash flow(2) to be between

NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Telehealth seems to be going strong with no signs of slowing down in the post-pandemic era. As telehealth companies develop programs to support online care, insurance companies like Humana have developed affordable healthcare plans for those seeking online healthcare. In addition to supporting telehealth, these companies are seeing an increase in the adoption of digital healthcare and cost savings associated with the same. Meanwhile, telehealth companies such as CloudMD Software & Services Inc. (TSXV:DOC) (OTCPK: DOCRF), Veeva Systems, Inc. (NYSE:VEEV), 1LifeHealthcare, Inc. (NASDAQ: ONEM), Teladoc Health (NYSE:TDOC), and Allscripts Healthcare Solution

Third quarter GAAP diluted EPS of $0.12; non-GAAP diluted EPS of $0.27, up 145% year-over-year Generated $57 million of cash flow from continuing operations and $35 million of free cash flow in the third quarter Increasing 2021 outlook for Adjusted EBITDA and free cash flow Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2021. Bookings(1) were $166 million in the third quarter of 2021. This result compares with $160 million in the third quarter of 2020. Contract revenue backlog totaled $3.9 billion as of September 30, 2021. Third quarter 2021 revenue was $369 million compared with $36

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended September 30, 2021 after the close of stock market hours on Thursday, November 4, 2021. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Third-Quarter 2021 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, November 4, 2021. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts I

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended June 30, 2021 after the close of stock market hours on Thursday, August 5, 2021. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Second-Quarter 2021 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, August 5, 2021. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor